{"id":"peginterferon-alpha-2a-ribavirin","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Pyrexia"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Peginterferon alpha-2a works by binding to the interferon-alpha receptor on the surface of cells, triggering a signaling cascade that activates the immune system to produce antiviral proteins and cytokines. Ribavirin, on the other hand, is a nucleoside analog that inhibits the replication of viral RNA by causing chain termination during viral RNA synthesis.","oneSentence":"Peginterferon alpha-2a is a recombinant form of interferon-alpha-2a, which is a protein that helps to stimulate the body's immune response to viral infections, while Ribavirin is an antiviral medication that inhibits viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:49.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6"}]},"trialDetails":[{"nctId":"NCT01634919","phase":"","title":"Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin","status":"COMPLETED","sponsor":"Seoul National University Boramae Hospital","startDate":"2012-07","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT00571714","phase":"NA","title":"Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-04-01","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01380938","phase":"PHASE3","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2018-12-01","conditions":"Chronic Hepatitis","enrollment":1150},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT00356486","phase":"PHASE4","title":"Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-10","conditions":"HIV Infections","enrollment":74},{"nctId":"NCT02601976","phase":"PHASE4","title":"Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2010-08","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01648140","phase":"PHASE2","title":"Dose Ranging of GSK2336805 in Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Hepatitis C, Chronic","enrollment":286},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT02107365","phase":"PHASE2","title":"Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-11","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":60},{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT02761629","phase":"PHASE4","title":"Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"Hepatitis C, Chronic","enrollment":180},{"nctId":"NCT01323244","phase":"PHASE3","title":"A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-12","conditions":"Hepatitis C","enrollment":142},{"nctId":"NCT01686789","phase":"PHASE4","title":"Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","startDate":"2011-01","conditions":"Chronic Hepatitis C Virus","enrollment":181},{"nctId":"NCT00537407","phase":"PHASE2","title":"A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":50},{"nctId":"NCT01724086","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":90},{"nctId":"NCT00874770","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-06","conditions":"Hepatitis C Infection","enrollment":74},{"nctId":"NCT01017575","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":55},{"nctId":"NCT00433069","phase":"PHASE2","title":"Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":5},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01479868","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-10","conditions":"Hepatitis C Virus Genotype-1","enrollment":109},{"nctId":"NCT01725542","phase":"PHASE2","title":"Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-12","conditions":"HCV-HIV Co-Infection","enrollment":75},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT01289496","phase":"PHASE2","title":"Ribavirin Dose Optimization for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-02","conditions":"Chronic Hepatitis C","enrollment":13},{"nctId":"NCT01290731","phase":"PHASE3","title":"A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":49},{"nctId":"NCT00028093","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2001-12","conditions":"Chronic Hepatitis C","enrollment":50},{"nctId":"NCT01684787","phase":"PHASE4","title":"Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients","status":"COMPLETED","sponsor":"Miguel Santin","startDate":"2006-09","conditions":"Chronic Hepatitis C","enrollment":80},{"nctId":"NCT00545233","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":155},{"nctId":"NCT00122616","phase":"PHASE3","title":"Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-11","conditions":"HIV Infections, Hepatitis C, Chronic","enrollment":52},{"nctId":"NCT00207311","phase":"PHASE4","title":"Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-08","conditions":"Fatty Liver, Hepatitis C","enrollment":30},{"nctId":"NCT01273948","phase":"PHASE1, PHASE2","title":"Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Peregrine Pharmaceuticals","startDate":"2011-01","conditions":"Hepatitis C","enrollment":66},{"nctId":"NCT00085917","phase":"PHASE2","title":"Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-06","conditions":"Hepatitis C, HIV Infections","enrollment":29},{"nctId":"NCT01142700","phase":"PHASE2","title":"A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Chronic Hepatitis C Virus Genotype 1","enrollment":""},{"nctId":"NCT01272310","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2011-01","conditions":"Chronic Hepatitis C","enrollment":36},{"nctId":"NCT01178996","phase":"PHASE3","title":"Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":552},{"nctId":"NCT00834860","phase":"PHASE4","title":"Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2007-01","conditions":"Chronic Hepatitis C, Hepatocellular Carcinoma","enrollment":179},{"nctId":"NCT00887081","phase":"PHASE4","title":"Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies","status":"UNKNOWN","sponsor":"Azienda Ospedaliera V. Cervello","startDate":"2009-01","conditions":"Hemoglobinopathies","enrollment":150},{"nctId":"NCT00055341","phase":"PHASE2","title":"Treatment of Hepatitis C in Hemophilic Patients With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-03","conditions":"HIV Infections, Hepatitis C, Hemophilia","enrollment":22},{"nctId":"NCT00575627","phase":"PHASE4","title":"Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":150},{"nctId":"NCT00466219","phase":"PHASE3","title":"Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2002-05","conditions":"Hepatitis C","enrollment":25},{"nctId":"NCT00158496","phase":"PHASE3","title":"Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-08","conditions":"Chronic Hepatitis C","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Peginterferon alpha-2a (40 kD) PEGASYS","Copegus or Rebetol, Ribavirin Teva"],"phase":"phase_3","status":"active","brandName":"Peginterferon alpha-2a + Ribavirin","genericName":"Peginterferon alpha-2a + Ribavirin","companyName":"Casa Sollievo della Sofferenza IRCCS","companyId":"casa-sollievo-della-sofferenza-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alpha-2a is a recombinant form of interferon-alpha-2a, which is a protein that helps to stimulate the body's immune response to viral infections, while Ribavirin is an antiviral medication that inhibits viral replication. Used for Chronic hepatitis C, Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}